Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATP-TCA-directed versus conventional neoadjuvant chemotherapy for resectable esophageal cancer
ChiCTR1900024882Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin and fluorouracil in esophageal cancer, Esophageal Squamous Cell Carcinoma (ESCC) and esophageal adenocarcinoma (EAC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Overall survival and Pathological response. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
cisplatinfluorouracil
03
Conditions
esophageal cancerEsophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on ChiCTR1900024882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024882.